title: Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine.
abstract: Caspofungin acetate (MK-0991) is a semisynthetic pneumocandin derivative being developed as a parenteral antifungal agent with broad-spectrum activity against systemic infections such as those caused by Candida and Aspergillus species. Following a 1-h i.v. infusion of 70 mg of [(3)H]MK-0991 to healthy subjects, excretion of drug-related material was very slow, such that 41 and 35% of the dosed radioactivity was recovered in urine and feces, respectively, over 27 days. Plasma and urine samples collected around 24 h postdose contained predominantly unchanged MK-0991, together with trace amounts of a peptide hydrolysis product, M0, a linear peptide. However, at later sampling times, M0 proved to be the major circulating component, whereas corresponding urine specimens contained mainly the hydrolytic metabolites M1 and M2, together with M0 and unchanged MK-0991, whose cumulative urinary excretion over the first 16 days postdose represented 13, 71, 1, and 9%, respectively, of the urinary radioactivity. The major metabolite, M2, was highly polar and extremely unstable under acidic conditions when it was converted to a less polar product identified as N-acetyl-4(S)-hydroxy-4-(4-hydroxyphenyl)-L-threonine gamma-lactone. Derivatization of M2 in aqueous media led to its identification as the corresponding gamma-hydroxy acid, N-acetyl-4(S)-hydroxy-4-(4-hydroxyphenyl)-L-threonine. Metabolite M1, which was extremely polar, eluting from HPLC column just after the void volume, was identified by chemical derivatization as des-acetyl-M2. Thus, the major urinary and plasma metabolites of MK-0991 resulted from peptide hydrolysis and/or N-acetylation.
authors.affiliation: Department of Drug Metabolism Merck Research Laboratories West Point, Pennsylvania, USA. suresh.k.balani@dupontpharma.com
authors.forename: S K
authors.initials: SK
authors.lastname: Balani
authors.forename: X
authors.initials: X
authors.lastname: Xu
authors.forename: B H
authors.initials: BH
authors.lastname: Arison
authors.forename: M V
authors.initials: MV
authors.lastname: Silva
authors.forename: A
authors.initials: A
authors.lastname: Gries
authors.forename: F A
authors.initials: FA
authors.lastname: DeLuna
authors.forename: D
authors.initials: D
authors.lastname: Cui
authors.forename: P H
authors.initials: PH
authors.lastname: Kari
authors.forename: T
authors.initials: T
authors.lastname: Ly
authors.forename: C E
authors.initials: CE
authors.lastname: Hop
authors.forename: R
authors.initials: R
authors.lastname: Singh
authors.forename: M A
authors.initials: MA
authors.lastname: Wallace
authors.forename: D C
authors.initials: DC
authors.lastname: Dean
authors.forename: J H
authors.initials: JH
authors.lastname: Lin
authors.forename: P G
authors.initials: PG
authors.lastname: Pearson
authors.forename: T A
authors.initials: TA
authors.lastname: Baillie
mesh_terms: D000900:Anti-Bacterial Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D000935:Antifungal Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D000077336:Caspofungin; D002851:Chromatography, High Pressure Liquid; D054714:Echinocandins; D006801:Humans; D055666:Lipopeptides; D009682:Magnetic Resonance Spectroscopy; D013058:Mass Spectrometry; D010455:Peptides; D010456:Peptides, Cyclic
chemical_list: D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D000077336:Caspofungin